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Abstract
AIM
To investigate the effect of clonidine on the cutaneous 
silent period (CSP) during spinal anesthesia. 
METHODS
A total of 67 adult patients were included in this ran-
domized, prospective, single-center, double-blind trial. 
They did not have neurological disorders and were 
scheduled for inguinal hernia repair surgery. This trial 
was registered on ClinicalTrials.gov (NTC03121261). 
The patients were randomized into two groups with 
regards to the intrathecally administered solution: (1) 
15 mg of 0.5% levobupivacaine with 50 µg of 0.015% 
clonidine, or (2) 15 mg  of 0.5% levobupivacaine alone. 
There were 34 patients in the levobupivacaine-clonidine 
(LC) group and 33 patients in the levobupivacaine (L) 
group. CSP and its latency were measured four times: 
prior to the subarachnoid block (SAB), after motor 
block regression to the 0 level of the Bromage scale, 
with ongoing sensory blockade, and both 6 and 24 h 
after SAB.
RESULTS
Only data from 30 patients in each group were 
analyzed. There were no significant differences bet-
ween the groups investigated preoperatively and after 
24 h. The CSP of the L group at the time point when 
the Bromage scale was 0 was 44.8 ± 8.1 ms, while in 
the LC group it measured 40.2 ± 3.8 ms (P = 0.007). 
The latency in the L group at the time point when the 
Bromage scale was 0 was 130.3 ± 10.2 ms, and in the 
LC group it was 144.7 ± 8.3 ms (P < 0.001). The CSP 
of the L group after 6 h was 59.6 ± 9.8 ms, while in 
the LC group it was 44.5 ± 5.0 ms (P  < 0.001). The 
latency in the L group after 6 h was 110.4 ± 10.6 ms, 
while in LC group it was 132.3 ± 9.7 ms (P  < 0.001).
CONCLUSION
Intrathecal addition of clonidine to levobupivacaine for 
SAB in comparison with levobupivacaine alone results 
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in a diminished inhibitory tonus and shortened CSP.
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Core tip: Cutaneous silent period (CSP) is an oligo-
synaptic spinal inhibitory reflex. The results of our study 
show that intrathecal administration of levobupivacaine 
with added clonidine, in comparison to levobupivacaine 
alone, yields a significantly shorter CSP and a significantly 
longer CSP latency during block regression following 
subarachnoid block (SAB) application. Accordingly, we 
can conclude that during SAB regression, a small dose 
of intrathecally administered clonidine ameliorates the 
inhibitory tonus and accelerates the conduction in the 
oligosynaptic spinal circuit.
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INTRODUCTION
The cutaneous silent period (CSP) is an oligosynaptic 
spinal inhibitory reflex largely evoked through small-
diameter Aδ-fibers[1,2]. The CSP begins after a noxious 
stimulus to a cutaneous sensory nerve during a voluntary 
muscle contraction and is evidenced by a transient 
lapse of electromyographic (EMG) activity[3]. According 
to some relevant studies, large-diameter afferent fibers 
with a low threshold action potential also contribute 
to EMG silencing through different mechanisms[4]. 
This is a non-invasive method that requires standard 
EMG equipment to investigate changes in the Aδ-
fibers and further elucidate the understanding and 
organization of the spinal inhibitory circuit as an integral 
part of this reflex. Namely, the duration of the CSP and 
its latency are altered in polyneuropathy and various 
diseases of the central nervous system, which lead to 
damage of the corticospinal and spinothalamic pathways 
as well as extrapyramidal disorders, suggesting a 
possible supraspinal influence on the CSP[5-8].
Clonidine, a selective partial agonist of the alpha-2 
receptors, when added to levobupivacaine and ad-
ministered intrathecally, enhances the effect of the 
local anesthetic, prolongs the sensory and motor block 
during subarachnoid block (SAB) and also prolongs the 
duration of postoperative analgesia[9,10]. The analgesic 
effects of clonidine are achieved through the Aδ, C-fibers 
as well as the substantia gelatinosa of the spinal cord. 
However, considering that its analgesic effect is the 
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strongest after intrathecal administration, it is deemed 
that the primary effective site of clonidine action is in the 
spinal cord[11,12]. Results from animal studies show the 
effect of clonidine on spinal reflexes[13-15]. Animal studies 
have shown that intrathecal administration of clonidine 
immediately resulted in a facilitation of the spinal reflexes 
in spinalized rats [mechanical or functional transection 
of the spinal cord (spinal block with procaine)][13]. Until 
now, the CSP has never been measured during neuraxial 
intrathecal blocking or after intrathecal administration 
of clonidine. We hypothesize that there could be a 
more pronounced and prolonged effect on the CSP 
after intrathecal administration of levobupivacaine 
and clonidine compared to levobupivacaine alone. The 
primary aim of this investigation was to demonstrate 
whether there is a difference in the duration and latency 
of CSP between a solution of levobupivacaine and 
clonidine together, in comparison with levobupivacaine 
alone, relative to the regression of the sensory and 
motor block and postoperative analgesia. A secondary 
aim was to determine whether there were differences 
in hemodynamic stability between the two studied 
groups, evidenced by changes in mean arterial pressure 
(MAP), heart rate (HR) and episodes of hypotension and 
bradycardia.
MATERIALS AND METHODS
General design and ethics
This was a randomized, prospective, single-center, 
double-blind trial conducted from May 2017 to October 
2017 in Clinical Hospital Dubrava, Zagreb, Croatia. The 
trial was approved by the local ethics committee of 
Clinical Hospital Dubrava (registration code 2391-1/15) 
and was registered at the Clinical Trials registry 
(ClinicalTrials.gov; registration number NTC03121261). 
Informed consent was obtained from all individual 
participants included in the study.
Patients
The study included male and female patients schedu-
led for elective inguinal hernia repair surgery who 
were under spinal anesthesia. Inclusion criteria were: 
Signed informed consent, ages 18-60 years, body 
mass index 18.5-24.9 kg/m2, and American Society 
of Anesthesiologists physical status Ⅰ or Ⅱ (Table 1). 
Exclusion criteria were: allergy to medications used 
in the research, coagulation disorders, use of opioids, 
uncontrolled psychiatric disorders, use of psychotropic 
drugs, infections in areas of intended site of block 
application, central nervous system damage, diabetes, 
systemic inflammatory conditions, malignant disease, 
alcoholism and polyneuropathy.
Study flow and anesthesia procedure
The patients were randomized through a free online 
randomization service [Urbaniak, G. C., and Plous, S. 
(2013). Research Randomizer (Version 4.0) Computer 
software] retrieved in May 2017 from http://www.
randomizer.org. Eligible patients were randomly allocated 
to receive either a SAB with levobupivacaine and 
clonidine [levobupivacaine - clonidine group (LC group, 
n = 34)] or levobupivacaine [levobupivacaine group (L 
group, n = 33)]. The neurologists and anesthesiologists 
conducting the clinical part of the study were not aware 
of the randomization numbers of individual patients, 
which was known only to two anesthesia technicians 
who were not involved in either the selection or follow-
up of patients. The control (L) group received 15 mg of 
0.5% levobupivacaine (Chirocaine®, Abbott Laboratories, 
Dublin, Ireland) with 0.33 mL of 0.9% saline and 
0.5 mL of 40% glucose, while the experimental (LC) 
group received 15 mg of 0.5% levobupivacaine with 
50 µg of 0.015% clonidine (0.015% Catapressan; 
Boehringer Ingelheim KG, Germany) and 0.5 mL of 
40% glucose. The CSP and its latency were measured 
1 d before surgery in order to avoid an influence from 
benzodiazepine premedication. All patients received 
premedication of 5 mg midazolam (Dormicum®, 
Roche) intramuscularly. In the operating theatre, all 
patients were non-invasively monitored with noninvasive 
blood pressure cuffs (Dräger Medical GmbH, Lübeck, 
Germany), peripheral oxygen saturation (SpO2) and HR 
via a pulse oximetry finger probe (SpO2 Sensor, Adults, 
Reusable, Dräger Medical GmbH, Lübeck, Germany). 
The unilateral SAB in the theatre was performed by an 
anesthesiologist unaware of the assigned treatment, and 
the patient was also unaware of the group to which they 
were randomly assigned. The patients were positioned 
in the horizontal lateral position. The SAB was performed 
using a 27-gauge Whitacre spinal needle at the lumbar 
(L)3-L4 spinal level, after which the patients remained 
in the lateral position until full block onset. A successful 
block was confirmed by pinprick test for sensory block 
and Bromage scale for motor block on the operative 
side[16]. Once the block was confirmed, the patients 
were positioned in the supine position. In all patients, 
a standard inguinal hernia repair surgical technique 
was performed by the two same surgeons, each with 
more than ten years of experience. Perioperatively, the 
MAP and HR were measured every 5 min. If there was 
an episode of hypotension (blood pressure decreases 
of more than 30% of the basal values), the patients 
received a bolus of 250 mL of 0.9% saline intravenously 
(IV). In the case of persisting hypotension, the patients 
were given 5-10 mg of ephedrine hydrochloride 
(Ephedrine, Biotika, Prague, Czech Republic) IV, while 
bradycardia (HR < 50 beats/min) was treated with 0.5 
mg of atropine IV. Postoperatively, the patients were 
admitted to the post-anesthesia care unit (PACU) for 
monitoring of vital functions and block regression. 
A blinded anesthesia technician recorded the times 
of block regression while testing the sacral (S) 1 
dermatome bilaterally, using the pinprick test method 
every 10 min and motor block regression every 10 
min with the Bromage scale[16]. The time of intrathecal 
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administration of the solutions was considered the 
measurement starting time. Once the vital parameters 
fulfilled criteria for discharge from PACU, assessed by 
a blinded anesthesia technician, a blinded anesthesio-
logist estimated the motor block regression as Bromage 
0 (ability to move the legs at the hip, knee and foot) 
while the sensory block was still present. At this time 
point, the second CSP measurement was performed in 
the EMG laboratory. After the CSP measurement, the 
patients were returned to the surgical ward where a 
ward technician recorded the pain intensity and return 
of sensation to the S 1 dermatome using a pinprick 
test. In accordance with previous studies, six hours 
after block application, analgesia was not present 
in the levobupivacaine group, while it was present 
in the levobupivacaine-clonidine group. The third 
measurement of CSP was conducted six hours after 
block application[9]. The fourth measurement of CSP was 
conducted 24 h after block application. The data were 
collected, coded and stored in a computer database. 
After statistical analysis, the blinding was broken.
Pain intensity assessment using the visual analogue 
scale
Pain intensity was measured using the visual ana-
logue scale (VAS, 0-10; VAS 0 = no pain; VAS 10 = 
maximal pain) prior to the surgical procedure, and 
every 3 h thereafter, during the 24-h postoperative 
period. The administration time of analgesics was 
also measured over the same period. In the case of 
moderate postoperative pain (> 3 VAS pain score < 6), 
the patients received 100 mg of ketoprofen (Ketonal, 
Sandoz) IV in 100 mL of 0.9% saline over 15 min. In 
the case of severe postoperative pain (VAS ≥ 6), the 
patients received 100 mg of tramadol hydrochloride 
(Tramal®, Herds) in 500 mL of 0.9 % saline over 30 
min[17]. According to previous studies, tramadol signi-
ficantly prolongs the duration of CSP, and these patients 
were excluded from the study[18]. 
CSP measurements
All included patients were referred to the department 
of neurology, where a blinded neurologist conducted 
a measurement of CSP and its latency with an EMG 
device (Medelec Sinergy, United Kingdom). The ambient 
temperature was controlled and maintained at values 
of 25℃-26℃. The patients were lying horizontally and 
a stimulating ring electrode was placed on the hallux 
of the leg on the operated side, while a plain surface 
registering electrode was placed above the ipsilateral 
tendon of the extensor digitorum brevis muscle. Sweep 
duration was set at 500 ms sensitivity at 0.5 mV and 
filters were set at 50 Hz-5000 Hz. The patients were 
instructed to attempt a sustained isometric dorsi-
flexion of the foot at about 50% of the maximum volun-
tary contraction (MVC) of the foot, considering that 
according to studies thus far, the mentioned strength 
of contraction does not affect the CSP[19]. MVC was 
determined by the manual muscle test, where 50% 
of MVC was determined by EMG activity, where MVC 
was shown over the entire screen and also followed 
by audiovisual feedback[20]. During a stable muscle 
contraction, a short pain stimulus of 250 V intensity and 
0.3 ms duration was released and was shown to be the 
optimal duration for every individual stimulus at evoking 
a CSP[21]. In the case where EMG silence was not able 
to be evoked, the duration of an individual stimulus was 
gradually increased at a rate of 0.1 ms to 1 ms, with the 
aim of achieving a reproducible duration of CSP and its 
latency[21]. The absence of EMG activity was analyzed. 
The early latency duration was measured from the 
commencement of stimulation to the beginning of con-
traction suppression, and this was representative of 
CSP latency. Duration of late latency was measured 
from commencement of stimulation to the beginning 
of a new contraction. The difference between the two 
latencies is the duration of the CSP. The measurement 
was repeated up to 10 times in 30 s intervals, and 
the arithmetic mean of the three best measurements 
yielded a complete EMG silence, making it possible for 
the longest duration of CSP to be calculated.
Sample size and power considerations
Analysis of test power was made for variance analy-
sis of repeated measurements according to the 
following parameters: two tested groups, four repeated 
measurements, significance α = 0.05, sample size 
consideration f = 0.25, and test power of 90%. This 
showed that 30 subjects per group were necessary to 
be included. Sample size consideration was made due 
Table 1  Patient and clinical data (n  = 30, mean ± SD), n  (%)
Patient data, duration of surgery Group
Levobupivacaine (n  = 30) Levobupivacaine + Clonidine (n  = 30)
Age (yr), mean ± SD 43.5 ± 9.2 46.7 ± 10.3
BMI (kg /m2), mean ± SD 23.3 ± 0.9 23.5 ± 0.5
Male gender 26 (86.7) 26 (86.7)
Female gender 4 (13.3) 4 (13.3)
ASA PS 2 10 (33.3) 8 (26.7)
Hypertension 3 (10.0) 4 (13.3)
Hernia localization, left side 17 (56.7) 16 (53.3)
Duration of surgery (min), mean ± SD 61.2 ± 12.9 62.8 ± 20.6
ASA PS: American Society of Anesthesiologists physical status; BMI: Body mass index.
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to the presumption of a similar previously published 
study[9]. Power analysis was carried out with the software 
support of G*Power for Windows, version 3.1.2” (http://
www.gpower.hhu.de/fileadmin/redaktion/Fakultaeten/
Mathematisch-Naturwissenschaftliche_Fakultaet/
Psychologie/AAP/gpower/GPowerManual.pdf).
Statistical analysis
Quantitative values are shown as the means, SD and 
95% CI. Kolmogorov-Smirnov test was used to analyze 
the distribution of quantitative data, and we applied 
appropriate parametric tests according to the data 
obtained. The comparisons between quantitative values 
were made with independent and dependent t-tests. 
The differences in categorical values were analyzed 
with Fisher’s exact tests. A two-way repeated measured 
analysis of variance (RM-ANOVA) was conducted to 
evaluate the null hypothesis that there are no changes 
in CSP, latency of CSP, VAS score and secondary 
hemodynamic parameters (MAP, HR) before, during 
and after spinal anesthesia (time and treatment over 
time interaction). Overall and time-specific treatment 
differences were generated with adjustment for 
multiplicity – Bonferroni correction. All other P values 
less than 0.05 were considered significant. IBM SPSS 
Statistics, version 21.0 was used in the analysis (www.
spss.com).
RESULTS
Four patients from the LC group and three from the L 
group were excluded from the trial due to discomfort 
during performance of the CSP test, and only 30 
patients per group were included in the analysis. Data 
about patient characteristics and duration of surgery 
did not show statistically significant differences between 
groups (Table 1). There were no significant differences 
in CSP or its latency between investigated groups 
preoperatively and after 24 h (Table 2, Figure 1A and 
1B). The CSP of the L group at the timepoint when 
the Bromage scale was 0 was 44.8 ± 8.1 ms, while in 
the LC group it measured 40.2 ± 3.8 ms (P = 0.007). 
The latency in the L group at the timepoint when the 
Bromage scale was 0 was 130.3 ± 10.2 ms, and in the 
LC group it was 144.7 ± 8.3 ms (P < 0.001). The CSP 
of the L group after 6 h was 59.6 ± 9.8 ms, while in the 
LC group it was 44.5 ± 5.0 ms (P < 0.001). The latency 
in the L group after 6 h was 110.4 ± 10.6 ms, while in 
LC group was 132.3 ± 9.7 ms (P < 0.001) (Table 2). 
When comparing preoperative and postoperative values 
of CSP duration, there was a statistically significant 
difference at timepoints of Bromage 0 in the L group 
(P < 0.001), the LC group (P = 0.007) and after 6 h in 
the LC group (P < 0.001) (Table 2 and Figure 1). When 
comparing the preoperative and postoperative values 
of CSP latency, there was a statistically significant 
difference at time points when the Bromage scale 
was 0 in both groups and after 6 h in the LC group (P 
< 0.001), while after 24 h there was no statistically 
significant difference in CSP duration or latency in 
either group (Table 2 and Figure 1). In addition, the 
LC group had a significantly longer regression time of 
the motor block (Bromage 0) on the operated side, a 
longer time of sensory regression in the S1 dermatome 
on the operated side (pinprick test), a longer duration 
of analgesia after SAB application, and longer times of 
first and second use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) (P < 0.001; Table 3). Time over group 
interactions were highly significant in both CSP and its 
latency, indicating the significant difference in CSP and 
latency dynamics between the investigated groups (P 
< 0.001; Figure 1A and 1B). There were no significant 
changes in MAP and HR values (Figure 2A and 2B), 
while the VAS score over 24 h was significantly higher 
in the L group (P < 0.001; Figure 3). Between groups, 
there was no statistically significant difference in the 
Table 2  Cutaneous silent period and latency of cutaneous silent period before, during and after spinal anesthesia (mean ± SD)
Levobupivacaine group 
(n  = 30)
Levobupivacaine + Clonidine group 
(n  = 30)
P 1 P 2 P 3 
CSP latency (ms) preoperative 108.2 ± 11.6 107.2 ± 11.6   0.737
CSP latency (ms) Bromage 0 130.3 ± 10.2 144.7 ± 8.3 < 0.001a < 0.001e < 0.001e
CSP latency (ms) 6 h 110.4 ± 10.6 132.3 ± 9.7 < 0.001b   0.459 < 0.001f
CSP latency (ms) 24 h 108.0 ± 10.6 107.5 ± 11.5   0.862   0.933   0.926
CSP (ms) preoperative 62.1 ± 9.5 61.3 ± 6.2   0.691
CSP (ms) Bromage 0 44.8 ± 8.1 40.2 ± 3.8    0.007c < 0.001g     0.007g
CSP (ms) 6 h 59.6 ± 9.8 44.5 ± 5.0 < 0.001d   0.325 < 0.001h
CSP (ms) 24 h 63.2 ± 9.9 62.9 ± 5.9   0.892   0.681   0.315
1P values for differences between groups, independent t-test; 2P values for differences compared to preoperative values in Levobupivacaine group, 
dependent t-test; 3P values for differences compared to preoperative values in Levobupivacaine + Clonidine group, dependent t-test. aIndicates significant 
differences in CSP latency between groups at the time point Bromage 0; bIndicates significant differences in CSP latency between groups 6 h after intrathecal 
administration of the solution; cIndicates significant differences in CSP duration between groups at the time point Bromage 0; dIndicates significant 
differences in CSP duration between groups 6 h after intrathecal administration of the solution; eIndicates significant differences in CSP latency comparing 
the preoperative and postoperative values at time point Bromage 0; fIndicates significant differences in CSP latency comparing the preoperative and 
postoperative values 6 h after intrathecal administration of the solution; gIndicates significant differences in CSP duration comparing the preoperative and 
postoperative values at time point Bromage 0; hIndicates significant differences in CSP duration comparing the preoperative and postoperative values 6 h 
after intrathecal administration of the solution. CSP: Cutaneous silent period.
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Table 3  Perioperative characteristics of subarachnoid block, duration of perioperative analgesia and amount of nonsteroidal anti-
inflammatory drug administration through whole time (over 24 h) - independent t -test (mean ± SD)
incidence of hypotension of the L group [n (%)-5/30 
(16.7%)] in comparison to the LC group [n (%)-10/30 
(33.3%)], in bradycardia [(n (%)-2/30 (6.7%)] in both 
groups, nor in the administration of ephedrine in the 
L group [n (%)-2/30 (6.7%)] in comparison to the LC 
group [n (%)-4/30 (13.3%)] and atropine [n (%)-2/30 
(6.7%)] in both groups, which were all subjected to 
Fisher’s exact tests.
DISCUSSION
The results of our study show that intrathecal admi-
nistration of levobupivacaine with added clonidine 
in comparison to levobupivacaine alone yields a sig-
nificantly shorter CSP and longer CSP latency during 
block regression after SAB application (Table 2). It is 
known that intrathecal administration of small doses of 
Levobupivacaine group 
(n  = 30)
Levobupivacaine + Clonidine group 
(n  = 30)
P
Regression time of the motor block (Bromage 0) - operated side 162.3 ± 25.6 285.3 ± 55.2 < 0.001
The time of sense regression in S1 dermatome - operated side (pinprick 
test) 
195.0 ± 22.4 326.3 ± 49.4 < 0.001
Duration of analgesia after SAB application 192.3 ± 20.3 364.3 ± 53.3 < 0.001
NSAID (iv.) 1st time (min) 205.3 ± 22.2 377.0 ± 51.6 < 0.001
NSAID (iv.) 2nd time (min) 388.3 ± 38.4 593.8 ± 54.9 < 0.001
Figure 1  Differences in duration of (A) silent cutaneous period and (B) latency of silent cutaneous period regarding the test groups (levobupivacaine - 
clonidine or levobupivacaine group) and the times of measurements (preoperatively, at the time point when the Bromage scale was 0, 6 h and 24 h after 
intrathecal administration of the solutions) according to the analysis of a variance for repeated measurements. Error bars represent mean values (95%CI). 
CSP: Cutaneous silent period; Preop: Preoperatively.
iv.: Intravenous; NSAID: Nonsteroidal anti-inflammatory drug; S1: Sacral; SAB: Subarachnoid block.
RM-ANOVA: F (3, 174) = 45.684, P  < 0.001
Vertical bars denote 95% confidence intervals
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Figure 2  The differences in the dynamics of (A) heart rate (beats per min) and (B) mean arterial pressure (mmHg) between the test groups (levobupivacaine 
- clonidine or levobupivacaine group) and the times (min) of the measurement before and after intrathecal administration of the solutions according to the 
analysis of a variance for repeated measures (0 indicates the initial values before performing subarachnoid block). Error bars represent mean values (95%CI). 
HR: Heart rate; MAP: Mean arterial pressure.
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clonidine (15-50 μg) as an adjuvant to local anesthetics 
in inguinal hernia repair surgery and hysterectomy 
can prolong the motor and sensory blockade as well 
as the duration of analgesia in comparison to local 
anesthetics alone, without significant differences in 
hemodynamic parameters (MAP and HR)[9,10,22,23]. In 
our study, we used a dose of 50 μg of clonidine in order 
to achieve a prolongation of the SAB, and showed 
the effects of intrathecal clonidine on the CSP without 
significant hemodynamic disturbances. In order to 
better portray the change in dynamics of CSP and 
latency, we conducted measurements at four different 
time points, as mentioned in the Methods section. The 
results of the first measurement of CSP and latency 
were similar between groups, which suggests adequate 
patient randomization (Table 2). In our study, we used a 
similar methodology as Svilpauskaite et al[21]. However, 
the results in our study showed a longer duration of 
CSP compared to the mentioned study, where the CSP 
duration was measured as 45.7 ± 11.8 ms for the left 
leg and 47.1 ± 10.3 ms for the right leg, which can be 
explained by differences in methodology. Namely, those 
authors used a maximal strength muscle contraction, 
while we used muscle contraction strength at 50% of 
the maximum, which could have influenced the duration 
of CSP in this study. According to the literature, CSP is 
shortest during a maximum muscle contraction when 
the CSP is most sensitive to changes and can disappear 
completely. According to published studies, muscle 
contractions at 10-50% MVC do not change the values 
of CSP duration[19]. The results in our study are similar 
to results obtained by Mota et al[24] (latency 112.8 ± 
17.4 ms, CSP 69.5 ± 19.0 ms), which can be explained 
by the muscle contraction strength of 30% MVC, as was 
used in their investigation. In the second measurement, 
we confirmed a statistically significant shortening of 
CSP duration and significant prolongation of latency 
in each group compared to the first measurement. In 
the second measurement, the duration of CSP was 
significantly shorter in the LC group, and the latency 
significantly longer (Table 2). These results concur 
with the results of previous studies[24]. Namely, Mota 
et al[24] had established a shortening in the duration 
of CSP and a gradual prolongation of its latency with 
the administration of a local anesthetic in the popliteal 
fossa for peripheral nerve blockade. In the mentioned 
study, CSP could be evoked immediately prior to the 
onset of motor block, but it was of a shorter duration 
and prolonged latency. Contrary to the study by Mota 
et al[24], we measured the CSP duration and latency 
during SAB regression. Similar to their investigation, 
CSP was measured during the phase when the block 
was still maintained in terms of sensory blockade, but 
without a motor component.  Thereby, the patients 
did not feel any pain in the S1 dermatome, but the 
EMG silence of shorter duration and prolonged latency 
could still be evoked. As explained by Mota et al[24], 
the EMG silence could be consequential to activation 
of large diameter fibers and is possibly an integral 
part of the cutaneomuscular reflex or a consequence 
of a small number of Aδ-fibers, whose function on 
nerve transmission is not hindered and is an integral 
part of the CSP[4]. The duration of the sensory block 
is determined by the return of sensation in the S1 
dermatome (pinprick test). Since we stimulated the 
sensory nerves of the hallux (L4, L5, S1 roots) in order 
to evoke a CSP, it is plausible that the EMG silencing in 
this situation could be due to both the partial regression 
of blockade of the Aδ-fibers after intrathecal local 
anesthetic administration, as well as the activation 
of functionally recovered Aδ-fibers[22]. In the second 
measurement, there was a difference in the duration of 
the CSP and its latency between the L and LC groups. 
In the LC group, the latency was significantly prolonged 
and the duration of CSP was significantly shorter 
than in the L group. In the third measurement, there 
was a persistent prolongation of CSP latency with a 
shortened duration of CSP in the LC group, while in the 
L group, the duration and latency of the CSP did not 
differ significantly from the initial measurement prior 
to SAB. We consider that the observed changes in the 
duration and latency of the CSP in the LC group are a 
consequence of clonidine administration.
Clonidine is a mixed alpha-1 and alpha-2 adrenergic 
agonist with predominant alpha-2 activity, and has an 
antihypertensive, sedative and analgesic effect[11]. It 
exhibits a synergistic effect when combined with local 
anesthetics. Clonidine increases the influx of potassium 
ions in isolated neurons, resulting in an augmentation 
and prolongation of local anesthetic effects[25,26]. In 
vitro studies have shown that alpha-2 adrenergic ago-
nists activate the postsynaptic alpha-2 adrenergic 
receptors and increase the influx of potassium ions, 
thereby causing a hyperpolarization of the neurons in 
the substantia gelatinosa. Meanwhile, the activation of 
presynaptic alpha-2 adrenergic receptors on the C and 
A-δ fibers inhibits the influx of calcium ions, resulting 
Figure 3  Differences in pain intensity using VAS (0-10; VAS 0 = no pain; VAS 
10 = maximal pain) regarding the test groups (levobupivacaine - clonidine 
group or levobupivacaine group) and the times (min) of the measurements 
according to the analysis of a variance for repeated measures (0 indicates 
the initial values immediately prior to performing subarachnoid block). Error 
bars represent mean values (95%CI). VAS: Visual analogue scale.
RM-ANOVA: F (8, 464) = 8.84, P  < 0.001
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in a decreased release of neurotransmitters[27-29]. Noxi-
ous stimuli in rats cause a polysynaptic flexor reflex-
hindlimb reflex, which is manifested by limb retraction 
and the tail-flick reflex. Animal studies have shown 
the effects of intrathecal administration of clonidine 
on the mentioned spinal reflexes, which depend on 
the functional integrity of the spinal cord and the 
administered dose of clonidine[13-15]. In an intact rat 
spine, the systemic administration of clonidine resulted 
in an attenuation of the flexor reflex, while in spinalized 
rats (mechanical or functional transection of the spinal 
column (spinal block with procaine)), the systemic or 
intrathecal administration of clonidine immediately re-
sulted in a facilitation of the reflexor response[13,15,30,31]. 
Small doses of intrathecally-administered clonidine in 
spinalized mice resulted in facilitation of the mentioned 
reflex, while administration of larger doses resulted in an 
inhibition of the reflex[31]. Spinalization of mice resulted 
in predominant alpha-1 effects over alpha-2 effects 
of clonidine. In mice with intact spines, the preserved 
supraspinal pathways prevented the alpha-1 effects of 
clonidine on spinal reflex pathways, while a functional 
transection of the spinal cord caused a disinhibition of 
supraspinal effects, with predominant alpha-1 effects of 
clonidine, resulting in a facilitation of the flexor reflex[13]. 
In contrast to the flexor reflex, which is polysynaptic, 
the CSP is an oligosynaptic reflex and little is known 
about the spinal inhibitory circuit of the CSP. The results 
of this study are in accordance with those of animal 
studies where small doses of intrathecally-administered 
clonidine in spinalized animals resulted in a facilitated 
flexor reflex response[13,15,30,31]. In contrast to studies 
on spinalized animals, which measured the effect of 
intrathecally-administered clonidine on the polysynaptic 
spinal reflex, in this study we investigated the effect 
of intrathecally-administered clonidine with neuraxial 
intrathecal anesthesia on an oligosynaptic spinal reflex, 
the CSP. The results of this study show that a small dose 
of intrathecally-administered clonidine during neuraxial 
intrathecal block ameliorates the inhibitory tonus and 
accelerates conduction in the oligosynaptic spinal circuit. 
This is likely via predominant alpha-1 adrenergic effects. 
Since this is a constituent of the CSP, the end effect was 
a shortened CSP and a prolongation of its latency.
The results of our study confirm the results of a 
previous study by Singh et al[9], who claimed that the 
advantages of intrathecal administration of clonidine at 
a dose of 50 mg as an adjuvant to a local anesthetic 
include the prolongation of analgesia, motor blockade, 
and sensory blockade with minimal hemodynamic 
changes, as evidenced by minimal changes in MAP, HR 
and ephedrine administration. As in previous studies, 
the results of our study confirm that after intrathecal 
administration of clonidine, measured pain intensity 
VAS scores are lower during the 24 h postoperative 
period. Consequently, patients required less NSAID 
administration[9,22].
There are some limitations to our study. One limi-
tation is that due to regression of the neuraxial block, 
there are a limited number of measurements of CSP 
duration and latency that can be conducted in order 
to avoid patient discomfort. This investigation did 
not measure the effect of intrathecally-administered 
clonidine on the CSP without local anesthetics, because 
in healthy subjects this would not be ethical and in 
surgical patients it would not provide sufficient anes-
thesia[22].
In conclusion, intrathecal administration of cloni-
dine as an adjuvant to levobupivacaine for SAB, in 
comparison with levobupivacaine alone, results in a 
shorter duration of CSP and a prolongation of CSP 
latency. Accordingly, we can conclude that during SAB 
regression, a small dose of intrathecally-administered 
clonidine ameliorates the inhibitory tonus and accelerates 
the conduction in the oligosynaptic spinal circuit.
ARTICLE HIGHLIGHTS
Research background
The silent cutaneous period (CSP) is an oligosynaptic spinal inhibitory reflex, 
largely mediated through small diameter Aδ-fibers. The CSP begins after a 
noxious stimulus of a cutaneous sensory nerve during a voluntary muscle 
contraction and is evidenced by a transient lapse of electromyographic (EMG) 
activity. This is a non-invasive method that requires standard EMG equipment 
to research changes in Aδ-fibers and can further elucidate the organization of 
the spinal inhibitory circuit as an integral part of this reflex.
Research motivation
The duration of CSP and its latency are altered in polyneuropathy and various 
diseases of the central nervous system, such as those that lead to damage 
of the corticospinal and spinothalamic pathways as well as extrapyramidal 
disorders. This suggests a possible supraspinal influence on the CSP. 
Clonidine, a selective partial agonist of alpha-2 receptors, when added to 
levobupivacaine and administered intrathecally, enhances the effect of the local 
anesthetic, prolongs the sensory and motor block during SAB, and prolongs the 
duration of postoperative analgesia. Until now, no other studies have measured 
the effect of intrathecally-administered clonidine on the CSP.
Research objectives
The research objective of this investigation was to examine the effect of 
clonidine on the CSP during SAB for inguinal herniorrhaphy.
Research methods
A total of 67 adult patients were included in this randomized, prospective, 
single-center, double-blind trial. They had no neurological disorders and were 
scheduled for inguinal hernia repair surgery. The patients were randomized 
into two groups with regard to the intrathecally-administered solution: either 
levobupivacaine with clonidine or levobupivacaine alone (34 patients in the 
levobupivacaine-clonidine (LC) group and 33 patients in the levobupivacaine (L) 
group). CSP and its latency were measured four times: prior to the SAB, after 
motor block regression to Bromage scale  level 0, with sensory blockade still 
present, and both 6 and 24 h after SAB.
Research results 
The LC group had significantly lower CSP duration (P = 0.007) and higher CSP 
latency (P < 0.001) values at the timepoint when the Bromage scale was 0 and 
after 6 h (P < 0.001). Comparing preoperative and postoperative values of CSP 
duration, there was a statistically significant difference at time points Bromage 
0 in the L group (P < 0.001), the LC group (P = 0.007) and after 6 h in the LC 
group (P < 0.001). When comparing the preoperative and postoperative values 
of CSP latency, there was a statistically significant difference at timepoints 
when the Bromage scale was 0 in both groups and after 6 h in the LC group (P 
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< 0.001).
Research conclusions
Intrathecal administration of clonidine as an adjuvant to levobupivacaine for 
SAB, in comparison with lavobupivacaine alone, results in a shorter duration 
of CSP and prolongation of CSP latency. Accordingly, we can conclude that 
during SAB regression, a small dose of intrathecally-administered clonidine 
ameliorates the inhibitory tonus and accelerates conduction in the oligosynaptic 
spinal circuit.
Research perspectives
CSP is an oligosynaptic spinal inhibitory reflex. Little is known about the factors 
that influence the functions of its spinal inhibitory circuits, which should be the 
subject of further investigations.
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